GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to
HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell
transplantation in patients with relapsed/refractory lymphoma.